Mesoblast Limited Key Patents Granted In United States Strengthen Commercial Rights And Broaden Clinical Indications

Published: May 24, 2011

Melbourne, May 24, 2011 (ABN Newswire) - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the company's product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office (USPTO) in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.

Back to news